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Abstract
Background: Neurodevelopment is orchestrated by a wide range of genes, and the genetic causes of
neurodevelopmental disorders are thus heterogeneous. We applied whole exome sequencing (WES) for molecular
diagnosis and in silico analysis to identify novel disease gene candidates in a cohort from Saudi Arabia with
primarily Mendelian neurologic diseases.
Methods: We performed WES in 31 mostly consanguineous Arab families and analyzed both single nucleotide and
copy number variants (CNVs) from WES data. Interaction/expression network and pathway analyses, as well as
paralog studies were utilized to investigate potential pathogenicity and disease association of novel candidate
genes. Additional cases for candidate genes were identified through the clinical WES database at Baylor Miraca
Genetics Laboratories and GeneMatcher.
Results: We found known pathogenic or novel variants in known disease genes with phenotypic expansion in 6
families, disease-associated CNVs in 2 families, and 12 novel disease gene candidates in 11 families, including KIF5B,
GRM7, FOXP4, MLLT1, and KDM2B. Overall, a potential molecular diagnosis was provided by variants in known
disease genes in 17 families (54.8 %) and by novel candidate disease genes in an additional 11 families, making the
potential molecular diagnostic rate ~90 %.
Conclusions: Molecular diagnostic rate from WES is improved by exome-predicted CNVs. Novel candidate disease
gene discovery is facilitated by paralog studies and through the use of informatics tools and available databases to
identify additional evidence for pathogenicity.
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Background
Neurodevelopmental disorders reflect the biology and
underlying complexity of nervous system developmental
processes, its constituent cellular and anatomical struc-
ture, and neurophysiological functions. The human brain
cortex consists of nearly 20 billion neurons, each express-
ing over 80 % of the roughly 25,000 known genes [1] and
participating in thousands of synaptic connections [2].
Deleterious gene variants can give rise to a wide range of
clinical presentations, which may be divided broadly into
either functional (i.e. intellectual disability) or structural
(i.e. malformations of cortical development) abnormalities
[3]. The study of developmental brain disorders is further
challenged by the high degree of genetic heterogeneity
observed, even within clinically well-defined disorders,
such as pontocerebellar hypoplasia [4]. These observa-
tions underscore both the necessity for and power of
comprehensive molecular studies in this field [5]. The
ultimate goal of these studies is to identify novel neuro-
developmental disease genes and establish potential
genotype/phenotype correlations, but the identities of
many of these genes remain elusive. Functional studies
in animal models and cell lines play a fundamental role
in the establishment of genotype/phenotype correla-
tions; however, the need for basic infrastructure and
time can be a bottleneck in processing the tremendous
amount of data generated by the extensive and wide-
spread use of new genomic tools [6]. The study of
Mendelian phenotypes, including neurodevelopmental
disorders, provides perhaps the most direct route to
identify the link between gene function and resultant
phenotype, and a foundation for investigating the under-
lying biology [7].
In this study, we used whole exome sequencing (WES)
to identify potentially deleterious gene variants in a mostly
consanguineous cohort from Saudi Arabia with either
structural or functional brain abnormalities. CNVs pre-
dicted from WES data provide some molecular diagno-
ses. In addition, investigation of paralogs associated
with similar phenotypes also facilitates the identifica-
tion of novel candidates. Moreover, cross-database gene




This cohort consists of 31 probands (13 males and 18 fe-
males) and their siblings and parents from families with
brain malformation and/or developmental delay/intellec-
tual disability. Additional file 1: Table S1 and Additional
file 2: Figure S1 provide the pedigree structures and clin-
ical information. All patients were evaluated by clinical
geneticists and neurologists.
Whole exome sequencing (WES) analysis
For the eight multiple-affected families, two members in
each family were studied by WES. For the 23 singleton
families, four were studied by WES as trios (i.e. affected
child plus both parents), and both proband and un-
affected twin sibling were studied in 1 family. In the
remaining families, only the proband was studied and
the DNA samples of other family members were used in
segregation analysis. DNA samples from selected indi-
viduals were sequenced by WES at the BCM Human
Genome Sequencing Center (HGSC) through the Baylor-
Hopkins Center for Mendelian Genomics (BHCMG)
research initiative. All experiments and analyses were
performed as previously described [8], and WES per-
formed in this study had 80X average depth-of-coverage,
with 93 % of base positions at a minimum of 20X.
PCR confirmation for WES data
We used standard PCR to confirm the variants identified
from WES and to perform segregation analysis. PCR
products were analyzed by Sanger sequencing (DNA Se-
quencing Core Facility at BCM).
Absence of heterozygosity (AOH) analysis
Calculated B-allele frequency information was deter-
mined from WES as the ratio of variant reads to total
reads in WES data and then processed using the Circu-
lar Binary Segmentation algorithm implemented in the
DNAcopy R bioconductor package [9]. We subtracted
0.5 from the calculated B-allele frequency. Segments
with the mean signal > 0.45 and size >1 kb were detected
as AOH regions. In the summary statistics in Additional
file 1: Table S4, for each proband, we provided the num-
ber, the maximum/minimum length, the median length,
the mean length, and the total length of potential AOH
regions (> = 0.5 Mb).
CNV analysis from WES data
We used CoNIFER [10], CoNVex (Sanger Centre, unpub-
lished), and HMZDelFinder (https://github.com/BCM-
Lupskilab/HMZDelFinder) to predict CNVs from WES
data. HMZDelFinder is an in-house-developed algorithm
implemented in the R programming language (R Core
Team 2014, http://www.R-project.org). WES data were
transformed into per-exon read depth, RPKM. Homo-
zygous/hemizygous deletions of exons were defined as
meeting three criteria: exons with RPKM <0.5, fre-
quency <0.5 % in the whole cohort, and located within
an AOH region (>1 kb), were called together with all
the exomes in BHCMG database.
Evaluation of candidate genes/variants
To assess the candidacy of novel disease genes, we ranked
each candidate gene in the cohort from most likely (red)
Charng et al. BMC Medical Genomics  (2016) 9:42 Page 2 of 14
to less (green) according to the following criteria [7]:
Genes found in multiple families with similar phenotypes
(3 points); Interactors/paralogs of the gene showing over-
lapping features in human (2 points); Animal studies of
the gene or its interactor/paralogs showing overlapping
features (2 points); Genomic region associated with the
phenotypes (1 point); Loss-of-function variant (2 points);
Predicted deleterious by multiple programs (1 point); rare
variants in multiple databases (1 point); Expressed in the
tissues/organs being affected (1 point).
We further classified variants for all known and novel
disease genes using the ACMG/AMP guidelines for variant
interpretation in Mendelian disorders (2015) [11] which
recommends classification of variant pathogenicity into 5
levels: pathogenic, likely pathogenic, variant of uncertain
significance (VUS), likely benign, and benign (Additional
file 1: Table S1). As these guidelines provide for additional
sub-classification of VUS, we used the term “VUS-favoring
likely pathogenic” to indicate variants for which there
is evidence of pathogenicity that does not meet criteria
for consideration as a likely pathogenic variant. In addition,
as the ACMG/AMP guidelines were developed for clinical
use and are not designed to address pathogenicity of vari-
ants in genes not yet established to be disease-causing, i.e.
candidate disease genes in gene discovery efforts, we have
categorized all variants in novel candidate disease genes as
VUS (Additional file 1: Table S1), while still providing evi-
dence for variant pathogenicity as appropriate.
Arrays and droplet PCR confirmation for CNVs
Deletion in GRID2 was confirmed using BCM chromo-
somal microarray version 10.2 [12]. Droplet digital (dd)
PCR for RPS6KC1 was performed using the QX200™
AutoDG™ Droplet Digital™ PCR System (Bio-Rad) fol-
lowing the manufacturer’s protocols and analyzed in
QuantaSoft™. Detailed conditions and primers are listed in
Additional file 3: Supplementary Materials and Methods.
Results
This genomics study includes 31 Arab families exhibit-
ing neurological disease phenotypes, among which 28
were reported to be consanguineous or from the same
tribe (Additional file 2: Figure S1). There were 23 (74 %)
families with a single affected subject and 8 (26 %) with
multiple affected family members. Nineteen (61 %) pro-
bands exhibited various structural brain malformations
and 12 (39 %) probands presented developmental delay/
intellectual disability (DD/ID) without brain malformations
(Fig. 1a). We hypothesize that disease causative genes in
the first group mainly affect brain development whereas
those in the second group mainly affect neuronal functions.
The cohort was further clinically assigned into phenotypic
subgroups including syndromic brain malformation, corpus
callosum abnormalities, cortical dysgenesis, microcephaly,
hindbrain malformation, white matter abnormalities, as
well as syndromic and non-syndromic DD/ID (Fig. 1b and
Additional file 1: Table S2). Individual families could be
assigned to multiple subgroups if they had multiple neuro-
developmental phenotypes.
We analyzed both SNVs and CNVs derived from the
exome data (Additional file 2: Figure S2). SNVs (includ-
ing small indels) were computationally filtered using the
allele frequency data from different exome databases and
bioinformatic predictions of damaging effects on the
corresponding protein. In addition to the public exome
variant databases, we also searched the variants and genes
in our internal BHCMG database with documented clin-
ical features as annotated in PhenoDB [13, 14]. Sanger se-
quencing of all candidate variants was performed for each
proband and all available relatives for confirmation and to
assess co-segregation with the phenotype. Only variants
that segregated with the phenotype are reported. Add-
itional analyses included an assessment of any previous
functional or disease studies of the gene, its orthologs in
other model organisms, and its paralogs or known interac-
tors in humans.
We identified rare genetic variants potentially contribut-
ing to the phenotypes in ~90 % (28/31) of families studied,
including 54.8 % for which a molecular diagnosis involved
variants in known disease genes (Fig. 1c-d and Additional
file 1: Table S3). Known or suspected consanguinity was
reported in 28/31 families and analysis of absence of het-
erozygosity (AOH) demonstrated one or more regions of
AOH > 0.5 Mb in all families with one or more variants in
known or candidate disease genes (Additional file 1:
Tables S2 and S4). Total personal genome AOH regions
ranged from 86.5 Mb to 507.5 Mb in the 28/31 families
with historical evidence for consanguinity and from
97.1 Mb to 118.8 Mb in the 3 families in which there
was no historical evidence for consanguinity. Most of
the variants in potential candidate disease genes that we
identified map to the AOH regions and are thus homozy-
gous recessive. In total, we identified 4 de novo variants
and 1 case with compound heterozygous alleles in candi-
date genes (Additional file 1: Table S1). One of the de novo
variants and the one case with compound heterozygous al-
leles, were found in consanguineous families (Additional
file 1: Tables S1 and S2).
Variants in known disease genes included previously
described pathogenic variants in 2 families (FARS2,
PORCN) and novel variants in 15 families (ACO2,
RNASEH2B, SARS2, MLC1, ARSA, HEXB, HIBCH,
HERC2, PHF6, GRID2, MYO5A, ANKRD11, KIAA0226,
C12ORF57,VPS13B, ATP2B3) (Additional file 1: Table S1),
6 of which are clinically observed to likely represent
phenotypic expansion from the previously reported associ-
ated traits (Table 1 and Additional file 1: Table S1). More-
over, we propose and provide evidenced-based ranking for
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Fig. 1 (See legend on next page.)
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12 novel candidate disease genes (GRM7, FOXP4, KIF5B,
KDM2B, MLLT1, RPS6KC1, CDK20, MAGED2,TMEM47,
AAR2, LOH12CR1, RSRC2) in 11 families (Table 2 and
Additional file 1: Table S1).
CNVs predicted from WES facilitate establishing a
potential etiologic molecular diagnosis
We used CoNIFER [10], CoNVex, and HMZDelFinder
to predict potential heterozygous and homozygous CNVs
based on exome data. Although many subjects have been
pre-screened with karyotyping and array CGH, this bio-
informatics approach enables higher resolution evaluation
of genomic regions poorly covered by clinical arrays,
including homozygous/hemizygous single exon drop-
out alleles. Among the 31 cases, we found compound
heterozygous variant alleles consisting of a SNV and a
CNV in a novel candidate gene RPS6KC1 (Figure 2
and Additional file 1: Table S1) as well as a homozy-
gous intragenic deletion in GRID2 (Additional file 2:
Figure S3).
The combined variants in RPS6KC1 were identified in
the proband (BAB6797) in family 025 with structural
brain malformation, including cortical dysgenesis and
corpus callosum abnormality (Fig. 2; Additional file 1:
Table S1). The SNV in RPS6KC1 was initially annotated
as homozygous (A/A) in the proband; segregation of this
variant in the parents demonstrated a heterozygous
(G/A) mother and a wild-type (G/G) father, suggesting
the possibility of a paternally inherited deletion unco-
vering the locus of the maternally inherited SNV.
Indeed, a heterozygous deletion was predicted by
CoNVex (chr1:g.213,403,839-213,445,978[hg19]; 42 kb,
including the last six exons of RPS6KC1) (Fig. 2a)
and CoNIFER (chr1:g.213,341,200-214,171,606[hg19];
83 kb, including the last seven exons of RPS6KC1
and the first two exons of the adjacent gene, data not
shown). Since the clinical array utilized has subopti-
mal coverage in this genomic interval, this suspected
deletion CNV was confirmed in both father and
the proband by droplet digital PCR (Fig. 2b and
(See figure on previous page.)
Fig. 1 Clinical categories in the cohort and summary of WES findings. a Based on the brain structural findings and accompanying features, this
cohort is grouped into nonsyndromic brain malformations (38 %), syndromic brain malformations (23 %), nonsyndromic DD/ID (16 %), and
syndromic DD/ID (23 %). b Based on the brain structural defects, families can be further grouped into corpus callosum abnormalities, cortical
dysgenesis, microcephaly, hindbrain malformations, and white matter changes; families may be counted in more than one of these groups.
c Summary of WES findings (including CNVs): We identified a known variant in a known gene in 2 families (6 %), 10 novel variants in known
genes in 9 families presenting reported clinical features (29 %), 7 novel variants in 6 known genes with phenotypic expansion in 6 families (19 %),
and 12 novel disease candidates in 11 families (36 %). d The disease genes/candidates identified in this study can be grouped into several
biological processes, including mitochondrial enzymes (metabolic or tRNA synthetase), lysosomal enzymes, motor proteins, trafficking proteins,
DNA replication, DNA repair, transcription, mRNA splicing, synaptic transmission, signaling pathways, apoptosis, and transmembrane proteins
Table 1 Known disease genes with phenotypic expansion
Family ID Gene Variant Zyg Clinical features of patients MIM Phenotypic expansion
037 BAB6843 MYO5A NM_000259.3:c.4200C > G:
p.Ser1400Arg
Hom DD, seizures, cerebellar atrophy,
nystagmus, dystonia
214450 Lacks classical Griscelli
syndrome phenotype of skin
hypopigmentation and silver-
grey hair
019 BAB6938 ANKRD11 NM_013275.5:c.5317G > T:
p.E1773*
Het DD/ID, hypotonia, esotropia, hyperopia,





022 BAB6787 KIAA0226 NM_014687.2:c.1642A > G:
p.Thr548Ala
Hom DD/ID, hypotonia, diffuse cortical
hypomyelination, contractures of






024 BAB6793 C12ORF57 NM_138425.3:c.53-2A > G Hom DD/ID, ADHD, bilateral hydronephrosis
and VUR, atrophic non-functioning
left kidney
218340 Vesicoureteric reflux and
bilateral hydronephrosis, small
non-functioning left kidney
034 BAB6835 VPS13B NM_152564.4:c.1219C > T:
p.Gln407*
Hom DD/ID, ADHD, microcephaly, hypotonia,
joint hyperlaxity, unsteady gait, severe
dental caries
216550 Autistic behavior, unsteady
gait, severe dental caries
026 BAB7039 ATP2B3 NM_001001344.2:c.3594G > T:
p.Lys1198Asn
Hem DD/ID, microcephaly, abnormal cortical
pattern, hypotonia and muscle atrophy,
oropharyngeal dysphagia, dental caries
302500 Microcephaly, abnormal cortical
pattern, muscle atrophy,
oropharyngeal dysphagia
DD/ID developmental delay/intellectual disability, ADHD attention deficit hyperactivity disorder, VUR Vesicoureteral Reflux, Hom homozygous, Het heterozygous,
Hem hemizygous; * stopgain
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Additional file 1: Table S5) and a customized high
density array CGH (Fig. 2c), and was demonstrated to
be 196,446 bp (chr1:g.213396378-213592823[hg19]; in-
cluding the last 7 exons of this gene) through break-
point junction PCR (Fig. 2d). RPS6KC1 mRNA is
expressed in the brain (Additional file 2: Figure S4a)
and may regulate sphingosine-1 phosphate signaling [15],
which is essential for neurogenesis and proper embryonic
development [16], suggesting RPS6KC1 as a candidate dis-
ease gene in this family.
The homozygous deletion in GRID2 was predicted by all
three programs in the personal genome WES from proband
(BAB6883) in family 041 who presented with hindbrain
malformation (Additional file 2: Figure S3a and Additional
file 1: Table S1). The deletion predicted by CoNIFER
(chr4:g.92007100-94138063[hg19]; 2.1 Mb, data not shown)
is much larger than that predicted by HMZDelFinder and
CoNVex (chr4:94006145-94032105[hg19]; 25 kb, data not
shown), as well as the size experimentally verified by BCM
clinical array (chr4:g.93985826-94074965[hg19]; 89 kb)
(Additional file 2: Figure S3b) [12]. It was further fine-
mapped to chr4:93978239-94078203[hg19] by breakpoint
junction PCR (99,965 bp) (Additional file 2: Figure S3c).
This homozygous deletion includes exons 3 and 4 of this
15 exon gene. GRID2 is the receptor for excitatory
glutamate neurotransmitter in the cerebellum [17] and
homozygous deletions, ranging from 37 kb–335 kb in
size, were reported to cause cerebellar ataxia and atrophy
(MIM#616204).
Sub-network analysis and cross-database mining provides
supporting evidence for candidate genes
In addition to RPS6KC1, we identified 11 other potential
novel candidate disease genes (Additional file 1: Table S1).
Table 2 Ranking for the candidate disease genes
The novel candidate genes identified in this cohort were ranked from most likely (red) to less (green) based on the scores using the following criteria: a. Genes
found in multiple families with similar phenotypes (3 points); b. Interactors/paralogs of the gene showing overlapping features in human (2 points); c. Animal
studies of the gene or its interactor/paralogs showing overlapping features (2 points); d. Genomic region associated with the phenotypes (1 point); e. Loss-of-function
variant (2 points); f. Predicted deleterious by multiple programs (1 point); g. Rare variants in multiple databases (1 point); h. Expressed in the tissues/organs being
affected (1 point). DD/ID: Developmental Delay/Intellectual Disability; ADHD: attention deficit hyperactivity disorder; PFO: Patent foramen ovale; VSD: Ventricular Septal
Defect; VUR: Vesicoureteral Reflux; Hom: homozygous; Het: heterozygous; cHet: compound heterozygous; Hem: hemizygous
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The supporting evidence for pathogenicity of these var-
iants is listed in Additional file 1: Table S1 and ranked
evidence supporting disease gene candidacy is listed in
Table 2. The protein network analysis for individual
candidate genes provides potential functional correlation
with the phenotypes, such as observed for CDK20,
LOH12CR1, and RSRC2 (Additional file 1: Table S1). We
performed additional bioinformatic analyses of mRNA ex-
pression in the brain at different developmental stages,
biological functional annotation, and network connectivity
based on protein-protein interactions to investigate the
novel and known genes as a cohort (Additional file 2:
Figure S4 and Figure S5). There is no obvious correl-
ation between the phenotypes and the temporal mRNA
expression in the brain. Although the network analysis
does not show significant enrichment, which likely re-
flects the small cohort size as well as heterogeneous
phenotypes and genetic causes (Fig. 1d and Additional
Fig. 2 A combination of SNV and CNV in RPS6KC1 in BAB6797. a CoNVex reveals a 42 kb heterozygous deletion (chr1:g.213403839_213445978del)
in RPS6KC1 in BAB6797 (family 025). There is a SNV (NM_001287219.1:c.2074G > A:p.Gly692Ser) uncovered by this deletion. Gray dotted line: the
read depth of other samples in the cohort; red line: the read depth for BAB6797; pink line: the predicted deletion region. b Droplet Digital PCR
(ddPCR) detects heterozygous deletion of RPS6KC1 in proband BAB6797 and father BAB6799 but not in mother BAB6798; primer pair targeting
RPS6KC1 around chr1:g.213415529[hg19] and three control primer pairs targeting copy-number neutral regions were used to perform ddPCR.
Absolute positive droplet concentrations (copies/ul) are plotted from ddPCR results for each primer pair in each sample. Positive droplet concentrations
of BAB6797 and BAB6799 for the RPS6KC1 primer pair (around 300 bp) are approximately half of the value in BAB6798 and the results from all control
primers (around 600 bp), indicating heterozygous deletion of the RPS6KC1 gene in BAB6797 and BAB6799, but not in BAB6798. Corresponding raw data
of ddPCR and primer sequences are shown in Table S5 . Ctrl, control. c This deletion is also confirmed by a customized array. The combination of SNV
and CNV in RPS6KC1 segregates in the family. d Breakpoint junction is mapped to chr1:g.213396378-213592823[hg19] by long-range PCR and Sanger
sequencing of the junction
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file 1: Table S1), we observed some sub-networks among a
subset of genes, such as MLLT1 and KDM2B (Additional
file 2: Figure S5a).
MLLT1 is an essential gene during development [18]
that co-activates SWI/SNF complexes and regulates his-
tone H3K79 demethylation [19]. The proband (BAB6950)
in family 058 with a potentially deleterious homozygous
variant in MLLT1 presents with developmental delay,
hypotonia, infantile spasm, and cortical dysgenesis
(Additional file 1: Table S1 and Fig. 3a). KDM2B is a
histone demethylase for H3K4 and H3K36 [20, 21]. The
homozygous variant is identified in two affected sib-
lings (BAB6693 and BAB6694) in family 009 presenting
developmental delay, hypotonia, and infantile spasms
Fig. 3 Segregation results and AOH plots of patients with variants in MLLT1, KDM2B, FOXP4, and KIF5B. In each panel, the segregation results are
shown to the left and AOH plots on the corresponding chromosomes are shown to the right. a In family 058, the proband (BAB6950) has
developmental delay, hypotonia, and infantile spasms with diffuse brain atrophy, delay and hypomyelination, as well as malformation of
cortical development. A homozygous variant in MLLT1 (NM_005934.3:c.1418G > A:p.Arg473Gln) is identified and segregates with the
phenotypes in the family. b In family 009, the proband (BAB6693) has developmental delay, hypotonia, and infantile spasms. A homozygous
variant in KDM2B (NM_032590.4:c.3050G > A:p.Arg1017His) is identified and segregates with the phenotypes in the family. c In family 028, the
proband (BAB6800) exhibits developmental delay, laryngeal hypoplasia, and ventricular septal defect (VSD). A homozygous variant in FOXP4
(NM_001012426.1:c.815delT:p.Lys272fs) is identified and segregates in the family. d In family 015, the proband (BAB6712) has developmental
delay, seizures, increased reflexes in upper and lower extremities, short stature with mild diffuse brain atrophy, and thinning of the corpus
callosum. The younger brother (BAB6713) is mildly affected with speech delay. A homozygous variant in KIF5B (NM_004521.2:c.2252A > G:p.His751Arg)
is identified and segregates with the phenotypes in the family, present in a homozygous state in both brothers
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(Fig. 3b and Additional file 1: Table S1). Variants in the
genes involved in chromatin remodeling and histone
modification are known to be associated with brain
malformation and DD/ID [7].
We previously reported that Drosophila genes with
multiple human homologs are more likely to be associ-
ated with human disorders [8]. We investigated paralogs
which have been associated with neurological disorders
by adding them into the interaction network and
observed sub-network enrichment (Additional file 2:
Figure S4b and S5b-d; Additional file 1: Table S6). Para-
logs of FOXP4, KIF5B, and GRM7, have been associated
with disorders presenting related phenotypes, which
provide supporting evidence for these novel candidate
disease genes (Fig. 3 and Additional file 1: Table S1).
FOXP4 may play a role in multiple systems affected in
the proband (BAB6800) in family 028, such as the larynx
and heart [22–24]. Moreover, FOXP4 and its paralogs,
FOXP1 and FOXP2, function together in several devel-
opmental processes [25, 26]. Variants in FOXP1 and
FOXP2 can lead to mental retardation with language im-
pairment (MIM#613670) and Speech-language disorder-
1 (MIM#602081), respectively. Genetic abnormalities in
FOXP1 are also associated with congenital heart defects
[27]. Therefore, FOXP4 may work together with FOXP1/
FOXP2 in brain function and heart development and con-
tribute to the phenotypes observed (Fig. 3c, Additional
file 2: Figure S5b, Additional file 1: Table S1).
A homozygous KIF5B variant was identified in the
proband (BAB6712) and his mildly affected brother
(BAB6713) in family 015 (Fig. 3d and Additional file 1:
Table S1). KIF5B and its paralogs, KIF5A and KIF5C
(Additional file 2: Figure S5c and Additional file 1: Table
S6), can transport RNA granules to the neuronal dendrites
for protein synthesis and translational silencing [28]. Loss
of KIF5B is embryonic lethal with severe growth retard-
ation in mice [29]. Moreover, variants in KIF5A and KIF5C
lead to spastic paraplegia (MIM#604187) and cortical dys-
plasia (MIM#615282), respectively. The severity of the
phenotypes in both disorders is variable, which may
potentially explain the different severity in the clinical
features between the affected siblings. The variability
may also be potentially explained by additional unknown
genetic variant(s) that exacerbate or suppress clinical
severity [30].
GRM6 and GRM8, the paralogs of GRM7, have been
implicated in neurodevelopmental diseases such as atten-
tion deficit hyperactivity disorder (ADHD) and autism
spectrum disorders (ASD) [31, 32]. Accordingly, recent
genomic studies also revealed an association between
GRM7 and ASD [33, 34]. Another related member, GRM1
(Additional file 1: Table S6), causes autosomal recessive
spinocerebellar ataxia type 13 (MIM#614831) which may
include cerebellar atrophy. A recent study indicates
GRM7 regulates neurogenesis in early developing mouse
brain [35]. Together, these data support GRM7 as a dis-
ease candidate in the two affected siblings (BAB6708 and
BAB6709) in family 014 presenting with hypotonia, brain
malformation including cortical atrophy, very thin and
shortened corpus callosum, and mild cerebellar volume
loss (Fig. 4; Additional file 1: Table S1). These examples il-
lustrate how expanding analyses to include paralogs may
help identify potential candidate disease genes.
To date, the candidate gene list submitted to Gene-
Matcher has not resulted in the identification of additional
families with phenotypes consistent with those observed
in our cohort. However, a similar analysis of candidate
genes in clinical WES data from the Baylor-Miraca Genet-
ics Laboratory revealed a family with compound heterozy-
gous GRM7 variants in two affected siblings presenting
similar clinical features, including cortical atrophy, very
thin and short corpus callosum, and hypotonia in the af-
fected members of family 014 (Fig. 4). This further sup-
ports our findings that GRM7 is a causative gene for both
families.
Discussion
We performed genomic studies in 31 mostly consan-
guineous Arab families with either brain malformation
or DD/ID and used bioinformatics analyses to identify
candidate disease genes and candidate variants likely
contributing to the observed clinical neurodevelopmen-
tal phenotypes. By considering minor allele frequency,
variant properties and predicted effects on protein struc-
ture and function, previous functional/disease studies of
the gene and its paralogs/interactors, as well as studying
both SNVs and CNVs, we identified known disease
genes in 55 % and candidate disease genes in 35 % of
families (Table 2 and Fig. 1c). The overall potential
molecular diagnostic rate considering both known and
candidate disease genes is around 90 %. This relatively
high rate likely reflects the fact that many neurodeve-
lopmental disease genes have been reported previously
and that families included are mostly consanguineous.
In this small Arab cohort, there are no shared causative/
candidate genes among the families even for the known
disease genes. In addition, these genes function in a variety
of biological processes, including chromatin modification,
transcriptional regulation, signal transduction, intracellular
transport, autophagy, mitosis, and apoptosis (Fig. 1d). The
diversity of genes found speaks to the heterogeneity of the
genetic causes and cellular processes underlying neuro-
logical disorders.
Highlights of a genomic study in a cohort with a high
consanguinity rate
We performed WES on two probands in each of the eight
families with multiple affected children (Additional file 2:
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Figure S1). A molecular diagnosis was not achieved in
families 006 and 018 since none of the candidate vari-
ants assessed segregate with the phenotype among the
family members. This may result from shared variants
either not being detected or potentially being filtered
out by the exome analysis pipeline. Alternatively, an in-
heritance model that is different than that assumed by
pedigree analysis may apply. Although in most of the
cases variation at a single locus may explain the clinical
features, one must consider the possibility that multiple
genetic causes may contribute in a given family and dif-
ferent genes may be involved in different affected family
members.
When affected siblings are observed to exhibit variable
clinical features in a family, there may still be a shared
genetic cause. In family 015 with one severely affected
proband and one mildly affected brother, we identified a
shared homozygous variant in KIF5B. Its paralogs, KIF5A
and KIF5C, are responsible for neurological disorders pre-
senting a variable severity of clinical features, which may
also be the case in this family. We cannot exclude the pos-
sibility that other gene variants in the proband may con-
tribute to the severity or that other variants in the mildly
affected brother may have a protective effect (Additional
file 1: Table S1) [30]. Nevertheless, the related functional





Fig. 4 Comparison of the two families carrying GRM7 variants. a Homozygous variant in GRM7 (NM_000844.3:c.461 T > C:p.Ile154Thr)
identified in family 014 with two affected children. b Compound heterozygous variants in GRM7 (NM_000844.3:c.1972C > T:p.Arg658Trp
and NM_000844.3:c.2024C > A:p.Thr675Lys) segregates in the family with two affected children identified in the BMGL database. c MRI
images of BAB6708 and BAB6709. d MRI images of BAB8506 and her brother. e Clinical features comparison among four patients
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major contributor, i.e. the molecular driver variant, for the
observed phenotypes (Additional file 1: Table S1).
In family 023, the proband exhibits low activity of
arylsulfatase A (ARSA), leading to metachromatic leu-
kodystrophy (MIM#250100). Targeted sequencing for
the previously reported ARSA variants showed a negative
result while WES reveals a novel homozygous ARSA vari-
ant (Additional file 1: Table S1), likely explaining the low
ARSA activity. In family 046, WES was performed on both
affected children. Although the analysis pipeline only re-
vealed a homozygous frameshift variant in ACO2 in the
proband (BAB7017) (Additional file 1: Table S1), Sanger
confirmation indicated that the affected sibling (BAB7018)
also has this homozygous variant. Retrospective re-
analysis of the original sequencing files showed that this
frameshift in BAB7018 was filtered out in the analysis
pipeline due to poor quality metrics. Similarly, frameshift
variants in DVL1, a recently reported disease gene for
Robinow Syndrome (MIM#616331) [36], also evaded
detection or were interpreted as missense by the WES
analysis pipeline. These examples point out a current
challenge in calling indels in WES pipelines. Filtering
criteria may improve through utilization of a ‘training set’
of cases with known indels. Alternatively, multiple calling
algorithms may be necessary for optimized indel detection.
One challenge in the study of consanguineous families
is the presence of multiple rare homozygous variants
within extended genomic intervals of AOH that are dis-
tributed throughout the genome (Additional file 1: Table
S4). This is exemplified by family 001 which is categorized
as unsolved because there are multiple candidate variants
in different genes that co-segregate with the phenotypes.
Other prioritization filters to identify the potential disease
contributing variants among rare homozygous variants
(Additional file 2: Figure S2 and Table 2) include: i) detect-
ing loss-of-function variants, ii) analyzing potential delete-
riousness of missense variants using multiple prediction
programs, iii) examining whether the gene is expressed in
disease related tissues, iv) assessing available functional
studies of the gene or its interactor/paralogs with overlap-
ping phenotypes, and v) finding the gene is a candidate
disease gene in multiple families with similar features. In
this study, there were 4 de novo and 2 compound hetero-
zygous variants found for the potential molecular diagno-
ses rendered; however, the majority of the disease or
candidate variants identified map within AOH regions
(Fig. 3 and Additional file 1: Table S4). Therefore, in some
families provided with candidate disease genes, there may
be additional contributors to the phenotypes (Additional
file 1: Table S1).
Estimating the potential inheritance mode based on
the pedigree structure before analysis facilitates the
speed of analysis. However, all potential inheritance
models should be investigated. In family 060, there are
eight children with only the youngest affected suggest-
ing a de novo event in the proband; therefore trio
WES was performed with analysis initially focused on
de novo variant identification. However, the molecular
analysis identified homozygous variants in RNASEH2B
(NM_001142279.2:c.356A >G:p.Asp119Gly) using a pre-
sumed recessive model (Additional file 1: Table S1).
Notably, one of the four de novo and the compound
heterozygous variants are found in consanguineous families
(Additional file 1: Tables S1 and S2), indicating the import-
ance of considering all inheritance modes during analysis.
Expanded phenotypes of the known disease-associated
genes and multifunction genes
In family 022, the proband with KIAA0226 variants ex-
hibits microcephaly without cortical dysgenesis, hindbrain
malformation, or corpus callosum abnormality, clinic-
ally distinct from the reported spinocerebellar ataxia
(MIM#615705). The reported case is a consanguineous
Saudi Arabia family with homozygous variants in the
same gene, suggesting phenotypic expansion potentially
related to intrinsic properties of the identified variants.
In family 037 with hindbrain malformation, we identified
a homozygous variant in MYO5A, which is responsible for
Griscelli syndrome (MIM#214450). MYO5A, an actin-
based motor protein, regulates many different cellular pro-
cesses, including melanosome transport in pigment cells
[37] and ER transport in Purkinje cells [38]. Different from
previously reported truncating variants in Griscelli syn-
drome, the missense variant in this family seems mainly to
affect cerebellar function.
Further empowering the analysis of the WES data by
CNV-detection tools
Predicting CNVs from exome data allows a more complete
analysis of possible pathogenic genomic variation, which
may result from a variety of mutational mechanisms. The
combination of a SNV and a CNV in RPS6KC1 provides a
possible explanation for the proband’s phenotypes in family
025 (Fig. 2, Table 2 and Additional file 1: Table S1). This
indicates that by using the read depth information in BAM
files and B-allele frequency in VCF files, one can detect
intragenic CNV. We anticipate that using next gener-
ation sequencing for both CNV and SNV analysis may
lead to more molecular diagnoses.
Paralogs with functional studies and disease association
provide additional supportive evidence
Previously, by combining the phenotypic information
from a large scale mutagenesis screen in fruit flies with
human exome and associated phenotype data from the
BHCMG database, we observed that fly genes with mul-
tiple human orthologs are more likely to be associated
with human disorders [8]. This observation led us to
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hypothesize that functional or genetic studies of para-
logs can facilitate candidate gene identification, as shown
in the cases of FOXP4, KIF5B, and GRM7, of which
paralogs are closely linked in the interaction network
(Additional file 1: Table S6 and Additional file 2: Figure S5).
Moreover, utilizing data from clinical sequencing and
computational programs for gene matching such as Gene-
Matcher can provide additional families to support our
candidate genes [13].
WES research study as a building block toward disease
gene discovery
In this research-based WES study, we identified several
potential candidate disease genes and provide supporting
evidence for each gene’s proposed association with dis-
ease [7] (Table 2 and Additional file 1: Table S1). We
also applied the ACMG variant classification criteria to
objectively demonstrate the evidence for pathogenicity
for these variants; notably, because the ACMG cri-
teria were designed for the clinical classification of
variants in known disease genes, we have classified all
variants associated with novel candidate disease genes
as VUS [11] (Additional file 1: Table S1). These vari-
ant classifications are meant to form a foundation for
further study. Nevertheless, this study provides informa-
tion that may serve as a building block for future disease-
gene discovery efforts.
Conclusions
In summary, by combining traditional WES analysis with
WES-derived CNV detection, database mining and bio-
informatic analyses of paralog, and interactome studies,
we attained a potential molecular diagnosis rate of
~90 % of families in this cohort. We also identified bial-
lelic variants representing recessive disease in a novel
disease gene GRM7 in two families with decreased cere-
bral and cerebellar volume. Our data suggest that this
combined strategy for WES analysis can provide a high
potential molecular diagnostic rate in this genetically het-
erogeneous cohort exhibiting neurologic disease.
Additional files
Additional file 1: Table S1. Summary of clinical features and disease/
candidate variants identified. The major clinical features and the disease/
candidate variants as well as the prediction scores and classifications for
damaging effect of the variants are listed. For Polyphen2 (Pph2), D for
probably damaging, P for possibly damaging, and B for benign. For LRT,
D for deleterious, N for neutral, and U for unknown. For MutationTaster
(MT), A for disease causing automatic, D for disease causing, N for
polymorphism, and P for polymorphism automatic. Moreover, this table
includes the ranking and ACMG criteria for each gene, the supporting
evidence and the discussion of other variants, as well as the frequency/
number of the variants in our internal CMG database, Atherosclerosis Risk
in Communities Study (ARIC), ExAC database, Thousand Genome project,
and NHLBI GO Exome Sequencing Project (ESP). pLI: probability of
loss-of-function (LoF) intolerance. Table S2. Categorization of families
based on major clinical features. Y: the family has this clinical feature;
N: the family does not have this clinical feature. Families with brain
malformations were not counted in the ID/DD groups, even if this
feature was present. Percentages of families with each feature are
shown at the bottom of the table. Table S3. Categorization of
disease genes/candidates by major clinical features. Table S4. AOH
metrics for the probands carrying known or candidate disease genes.
Table S5. Raw data of ddPCR in RPS6KC1 in family 025. Table S6. Homologs
of disease genes/candidates between human and fruit fly. The HCOP
website (http://www.genenames.org/cgi-bin/hcop) was used to
identify the fly homologs of the identified disease/candidate genes,
listed in the upper panel. These fly homologs are then used to search for
additional human homologs to find paralogs of the original human genes,
as shown in the bottom part of the list. (XLS 165 kb)
Additional file 2: Figure S1. Thirty one Arab family pedigrees in this
study. Family numbers are given as numeric series and individual IDs as
BAB series. They are arranged into: known variant in known gene (green),
novel variant in known gene (light red), phenotypic expansion (blue),
novel disease candidates (light orange), and unsolved cases (gray). Gray
shading indicates a minor phenotype. Figure S2. Workflow of WES analysis.
The SNVs predicted to have (probably) damaging effects are filtered with
the allele frequency data from Atherosclerosis Risk in Communities Study
(ARIC) (http://drupal.cscc.unc.edu/aric/), NHLBI GO Exome Sequencing
Project (ESP), Seattle, WA (http://evs.gs.washington.edu/EVS/), 1000
Genomes Project (http://www.1000genomes.org), and Exome Aggregation
Consortium (ExAC) Cambridge, MA (http://exac.broadinstitute.org)
[Oct 2014] and Baylor-Hopkins Center for Mendelian Genomics (BHCMG)
database with more than 5,000 exomes. WES data are also used to predict
CNVs. The information of the paralogs of candidate genes provides
supporting evidence for the findings. Moreover, cross-database gene
mining identifies additional cases. Figure S3. CNV prediction identifies a
homozygous deletion in GRID2 in BAB6883. a HMZDelFinder reveals a
homozygous deletion in GRID2 (chr4:g.94006145_94032105del). The lower
threshold for RPKM is 0.5 and upper threshold is 1. b This deletion is
confirmed by clinical array (chr4:g.93,985,826_94,074,965del) and
segregates with phenotypes in the family. c Breakpoint junction maps to
chr4:g.93,978,239_94,078,203del. Figure S4. Network analysis of known and
candidate genes. a Temporal RNA expression in brain. b The protein-protein
interaction network: Interaction STRING scores are displayed in an upper
triangular heatmap. Low and high values are represented in blue and red,
respectively. Figure S5. Protein interaction network of the candidate genes.
a KDM2B and MLLT1 are in the chromatin remodeling sub-network. b
FOXP4 and its paralogs. c KIF5B and its paralogs. d GRM7 and its related
members. (ZIP 4859 kb)
Additional file 3: Suplementary Materials and Methods. (DOCX 16 kb)
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